Elanco Animal Health (NYSE:ELAN) Issues Q4 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its fourth quarter earnings guidance on Thursday morning. The company provided EPS guidance of $0.13-$0.18 for the period, compared to the consensus EPS estimate of $0.16. The company issued revenue guidance of $1.00-$1.03 billion, compared to the consensus revenue estimate of $1.01 billion. Elanco Animal Health also updated its FY 2024 guidance to 0.890-0.950 EPS.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ELAN. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 target price on shares of Elanco Animal Health in a research report on Thursday, September 19th. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $17.00 to $15.00 in a research report on Thursday, September 19th. Finally, Barclays cut their target price on shares of Elanco Animal Health from $22.00 to $19.00 and set an “overweight” rating on the stock in a research report on Monday, October 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $17.00.

Elanco Animal Health Stock Performance

Shares of ELAN stock opened at $13.30 on Thursday. The stock has a 50-day moving average of $13.97 and a 200-day moving average of $14.72. Elanco Animal Health has a one year low of $10.19 and a one year high of $18.80. The stock has a market cap of $6.57 billion, a PE ratio of -5.04, a price-to-earnings-growth ratio of 1.31 and a beta of 1.41. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.93 and a quick ratio of 1.75.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Thursday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. The business had revenue of $1.18 billion during the quarter, compared to analysts’ expectations of $1.15 billion. During the same period in the prior year, the business earned $0.18 EPS. Elanco Animal Health’s revenue for the quarter was up 12.0% compared to the same quarter last year. As a group, sell-side analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

Insider Activity at Elanco Animal Health

In related news, Director Michael J. Harrington acquired 3,500 shares of the business’s stock in a transaction dated Thursday, August 22nd. The stock was bought at an average price of $14.85 per share, with a total value of $51,975.00. Following the acquisition, the director now owns 81,094 shares in the company, valued at $1,204,245.90. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Elanco Animal Health news, Director Michael J. Harrington acquired 3,500 shares of the company’s stock in a transaction on Thursday, August 22nd. The shares were purchased at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the purchase, the director now directly owns 81,094 shares of the company’s stock, valued at approximately $1,204,245.90. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jeffrey N. Simmons acquired 100,000 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was purchased at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the completion of the acquisition, the chief executive officer now owns 145,000 shares in the company, valued at approximately $1,886,450. This represents a 200.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.57% of the stock is owned by company insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.